{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T11:28:13Z","timestamp":1793878093516,"version":"4.7.0"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100013412","name":"Sanofi Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s13555-026-01804-z","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T11:29:35Z","timestamp":1780658975000},"page":"3659-3686","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The State of the Art in Chronic Prurigo Nodularis"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7603-0300","authenticated-orcid":false,"given":"Esther","family":"Serra-Baldrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngeles","family":"Fl\u00f3rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Juli\u00e0 Manresa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"Ortiz de Frutos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9-Juan","family":"Pereyra-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bibiana","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignasi","family":"Figueras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"issue":"7","key":"1804_CR1","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1111\/jdv.14570","volume":"32","author":"MP Pereira","year":"2018","unstructured":"Pereira MP, Steinke S, Zeidler C, Forner C, Riepe C, Augustin M, et al. European Academy of Dermatology and Venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. J Eur Acad Dermatol Venereol. 2018;32(7):1059\u201365.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1804_CR2","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jaad.2019.07.022","volume":"82","author":"HF St\u00e4nder","year":"2020","unstructured":"St\u00e4nder HF, Elmariah S, Zeidler C, Spellman M, St\u00e4nder S. Diagnostic and treatment algorithm for chronic nodular prurigo. J Am Acad Dermatol. 2020;82(2):460\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1804_CR3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3390\/medicines6040097","volume":"6","author":"CD Kwon","year":"2019","unstructured":"Kwon CD, Khanna R, Williams KA, Kwatra MM, Kwatra SG. Diagnostic workup and evaluation of patients with prurigo nodularis. Medicines. 2019;6(4):97.","journal-title":"Medicines"},{"issue":"8","key":"1804_CR4","doi-asserted-by":"publisher","first-page":"adv00119","DOI":"10.2340\/00015555-3471","volume":"100","author":"T Todberg","year":"2020","unstructured":"Todberg T, Zachariae C, Skov L. Treatment and burden of disease in a cohort of patients with prurigo nodularis: a survey-based study. Acta Derm Venereol. 2020;100(8):adv00119.","journal-title":"Acta Derm Venereol"},{"issue":"8","key":"1804_CR5","doi-asserted-by":"publisher","first-page":"e303","DOI":"10.1111\/jdv.15584","volume":"33","author":"A Calugareanu","year":"2019","unstructured":"Calugareanu A, Jachiet M, Lepelletier C, De Masson A, Rybojad M, Bagot M, et al. Dramatic improvement of generalized prurigo nodularis with dupilumab. J Eur Acad Dermatol Venereol. 2019;33(8):e303\u20134.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1804_CR6","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.det.2018.02.003","volume":"36","author":"C Zeidler","year":"2018","unstructured":"Zeidler C, Yosipovitch G, St\u00e4nder S. Prurigo nodularis and its management. Dermatol Clin. 2018;36(3):189\u201397.","journal-title":"Dermatol Clin"},{"issue":"7","key":"1804_CR7","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1111\/ced.14722","volume":"46","author":"P Aggarwal","year":"2021","unstructured":"Aggarwal P, Choi J, Sutaria N, Roh YS, Wongvibulsin S, Williams KA, et al. Clinical characteristics and disease burden in prurigo nodularis. Clin Exp Dermatol. 2021;46(7):1277\u201384.","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"1804_CR8","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/bjd.21698","volume":"187","author":"L Misery","year":"2022","unstructured":"Misery L. Chronic prurigo. Br J Dermatol. 2022;187(4):464\u201371.","journal-title":"Br J Dermatol"},{"key":"1804_CR9","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2147\/CCID.S188070","volume":"12","author":"EH Kowalski","year":"2019","unstructured":"Kowalski EH, Kneiber D, Valdebran M, Patel U, Amber KT. Treatment-resistant prurigo nodularis: challenges and solutions. Clin Cosmet Investig Dermatol. 2019;12:163\u201372.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"10","key":"1804_CR10","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1111\/jdv.16309","volume":"34","author":"MP Pereira","year":"2020","unstructured":"Pereira MP, Hoffmann V, Weisshaar E, Wallengren J, Halvorsen JA, Garcovich S, et al. Chronic nodular prurigo: clinical profile and burden. A European cross-sectional study. J Eur Acad Dermatol Venereol. 2020;34(10):2373\u201383.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1804_CR11","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1159\/000534660","volume":"240","author":"M Yin","year":"2024","unstructured":"Yin M, Yang C, Guo Y, Yang X, Dou X. Comorbidities of chronic prurigo: a systematic review and meta-analysis. Dermatology. 2024;240(1):32\u201341.","journal-title":"Dermatology"},{"issue":"12","key":"1804_CR12","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.it.2018.10.001","volume":"39","author":"MR Mack","year":"2018","unstructured":"Mack MR, Kim BS. The itch\u2013scratch cycle: a neuroimmune perspective. Trends Immunol. 2018;39(12):980\u201391.","journal-title":"Trends Immunol"},{"issue":"8","key":"1804_CR13","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1056\/NEJMe1916733","volume":"382","author":"SG Kwatra","year":"2020","unstructured":"Kwatra SG. Breaking the itch\u2013scratch cycle in prurigo nodularis. N Engl J Med. 2020;382(8):757\u20138.","journal-title":"N Engl J Med"},{"issue":"2","key":"1804_CR14","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jid.2024.06.1276","volume":"145","author":"SG Kwatra","year":"2025","unstructured":"Kwatra SG, St\u00e4nder S, Yosipovitch G, Kim BS, Levit NA, O\u2019Malley JT. Pathophysiology of prurigo nodularis: neuroimmune dysregulation and the role of type 2 inflammation. J Investig Dermatol. 2025;145(2):249\u201356.","journal-title":"J Investig Dermatol"},{"issue":"3","key":"1804_CR15","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.jaad.2020.07.025","volume":"84","author":"S Elmariah","year":"2021","unstructured":"Elmariah S, Kim B, Berger T, Chisolm S, Kwatra SG, Mollanazar N, et al. Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus. J Am Acad Dermatol. 2021;84(3):747\u201360.","journal-title":"J Am Acad Dermatol"},{"key":"1804_CR16","unstructured":"European Medicines Agency. Product Information: Dupixent\u00ae (dupilumab) [cited 2026 February 24]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/dupixent-epar-product-information_en.pdf."},{"key":"1804_CR17","unstructured":"European Medicines Agency. Product Information: Nemluvio\u00ae (nemolizumab) [cited 2026 February 24]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nemluvio-epar-product-information_en.pdf."},{"key":"1804_CR18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s41073-019-0064-8","volume":"4","author":"C Baethge","year":"2019","unstructured":"Baethge C, Goldbeck-Wood S, Mertens S. SANRA\u2014A scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019;4:5.","journal-title":"Res Integr Peer Rev"},{"issue":"2","key":"1804_CR19","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.jid.2019.07.697","volume":"140","author":"AH Huang","year":"2020","unstructured":"Huang AH, Canner JK, Khanna R, Kang S, Kwatra SG. Real-world prevalence of prurigo nodularis and burden of associated diseases. J Investig Dermatol. 2020;140(2):480\u20133 e4.","journal-title":"J Investig Dermatol"},{"key":"1804_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/medicines7010004","author":"JM Hughes","year":"2020","unstructured":"Hughes JM, Woo TE, Belzberg M, Khanna R, Williams KA, Kwatra MM, et al. Association between prurigo nodularis and etiologies of peripheral neuropathy: suggesting a role for neural dysregulation in pathogenesis. Medicines (Basel). 2020. https:\/\/doi.org\/10.3390\/medicines7010004.","journal-title":"Medicines (Basel)"},{"issue":"9","key":"1804_CR21","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1016\/j.jaip.2020.05.051","volume":"8","author":"KA Whang","year":"2020","unstructured":"Whang KA, Mahadevan V, Bakhshi PR, Williams KA, Gabriel S, Chavda R, et al. Prevalence of prurigo nodularis in the United States. J Allergy Clin Immunol Pract. 2020;8(9):3240\u20131.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"1804_CR22","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/j.1468-3083.2012.04481.x","volume":"27","author":"A Iking","year":"2013","unstructured":"Iking A, Grundmann S, Chatzigeorgakidis E, Phan NQ, Klein D, St\u00e4nder S. Prurigo as a symptom of atopic and non-atopic diseases: aetiological survey in a consecutive cohort of 108 patients. J Eur Acad Dermatol Venereol. 2013;27(5):550\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1804_CR23","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2340\/00015555-2774","volume":"98","author":"C Zeidler","year":"2018","unstructured":"Zeidler C, Tsianakas A, Pereira M, Stander H, Yosipovitch G, St\u00e4nder S. Chronic prurigo of nodular type: a review. Acta Derm Venereol. 2018;98(2):173\u20139.","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"1804_CR24","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1093\/bjd\/ljae207","volume":"191","author":"D Bahloul","year":"2024","unstructured":"Bahloul D, Hudson R, Balogh O, Mathias E, Heywood B, Hubbuck E, et al. Prevalence, incidence and treatment patterns of prurigo nodularis in England: a retrospective database analysis. Br J Dermatol. 2024;191(4):548\u201355.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1804_CR25","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/bjd.21032","volume":"187","author":"CL Morgan","year":"2022","unstructured":"Morgan CL, Thomas M, St\u00e4nder S, Jabbar-L\u00f3pez ZK, Piketty C, Gabriel S, et al. Epidemiology of prurigo nodularis in England: a retrospective database analysis. Br J Dermatol. 2022;187(2):188\u201395.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1804_CR26","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1093\/bjd\/ljae259","volume":"191","author":"JM Carrascosa","year":"2024","unstructured":"Carrascosa JM, Munera-Campos M. Prurigo nodularis: the difference between knowing the path and walking the path. Br J Dermatol. 2024;191(4):480\u20131.","journal-title":"Br J Dermatol"},{"issue":"10","key":"1804_CR27","doi-asserted-by":"publisher","first-page":"T967","DOI":"10.1016\/j.ad.2024.09.011","volume":"115","author":"J Ortiz de Frutos","year":"2024","unstructured":"Ortiz de Frutos J, Serra Baldrich E, Trib\u00f3 Boixareu MJ, Armario Hita JC, Carrascosa Carrillo JM, Figueras Nart I, et al. Consensus on the diagnostic algorithm for chronic nodular prurigo. Actas Dermosifiliogr. 2024;115(10):T967\u201373.","journal-title":"Actas Dermosifiliogr"},{"issue":"5","key":"1804_CR28","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/jdv.19700","volume":"38","author":"S St\u00e4nder","year":"2024","unstructured":"St\u00e4nder S, Ketz M, Akumo D, Kossack N, Pignot M, Chavda R, et al. Comorbidities, healthcare resource utilization & treatment pattern among patients with prurigo nodularis, compared to a benchmark in Germany: a real-world evidence claims data study. J Eur Acad Dermatol Venereol. 2024;38(5):883\u201394.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1804_CR29","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.jaci.2018.09.005","volume":"142","author":"G Yosipovitch","year":"2018","unstructured":"Yosipovitch G, Rosen JD, Hashimoto T. Itch: from mechanism to (novel) therapeutic approaches. J Allergy Clin Immunol. 2018;142(5):1375\u201390.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1804_CR30","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/ejp.767","volume":"20","author":"C Zeidler","year":"2016","unstructured":"Zeidler C, St\u00e4nder S. The pathogenesis of prurigo nodularis: \u2018super-itch\u2019 in exploration. Eur J Pain. 2016;20(1):37\u201340.","journal-title":"Eur J Pain"},{"issue":"12","key":"1804_CR31","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1111\/jdv.15107","volume":"32","author":"MP Pereira","year":"2018","unstructured":"Pereira MP, Basta S, Moore J, St\u00e4nder S. Prurigo nodularis: a physician survey to evaluate current perceptions of its classification, clinical experience and unmet need. J Eur Acad Dermatol Venereol. 2018;32(12):2224\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1804_CR32","doi-asserted-by":"publisher","first-page":"138","DOI":"10.2500\/aap.2019.40.4217","volume":"40","author":"MA Pasha","year":"2019","unstructured":"Pasha MA, Patel G, Hopp R, Yang Q. Role of innate lymphoid cells in allergic diseases. Allergy Asthma Proc. 2019;40(3):138\u201345.","journal-title":"Allergy Asthma Proc"},{"issue":"12","key":"1804_CR33","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1111\/exd.14014","volume":"28","author":"C Nakashima","year":"2019","unstructured":"Nakashima C, Ishida Y, Kitoh A, Otsuka A, Kabashima K. Interaction of peripheral nerves and mast cells, eosinophils, and basophils in the development of pruritus. Exp Dermatol. 2019;28(12):1405\u201311.","journal-title":"Exp Dermatol"},{"key":"1804_CR34","doi-asserted-by":"publisher","first-page":"888","DOI":"10.3389\/fimmu.2018.00888","volume":"9","author":"IS Junttila","year":"2018","unstructured":"Junttila IS. Tuning the cytokine responses: an update on interleukin (IL)-4 and IL-13 receptor complexes. Front Immunol. 2018;9:888.","journal-title":"Front Immunol"},{"issue":"10","key":"1804_CR35","doi-asserted-by":"publisher","first-page":"5164","DOI":"10.3390\/ijms25105164","volume":"25","author":"HJ Yook","year":"2024","unstructured":"Yook HJ, Lee JH. Prurigo nodularis: pathogenesis and the horizon of potential therapeutics. Int J Mol Sci. 2024;25(10):5164.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1804_CR36","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1016\/j.jaci.2022.02.021","volume":"149","author":"P Kolkhir","year":"2022","unstructured":"Kolkhir P, Pyatilova P, Ashry T, Jiao Q, Abad-Perez AT, Altrichter S, et al. Mast cells, cortistatin, and its receptor, MRGPRX2, are linked to the pathogenesis of chronic prurigo. J Allergy Clin Immunol. 2022;149(6):1998\u20132009 e5.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1804_CR37","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","volume":"171","author":"LK Oetjen","year":"2017","unstructured":"Oetjen LK, Mack MR, Feng J, Whelan TM, Niu H, Guo CJ, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell. 2017;171(1):217\u201328 e13.","journal-title":"Cell"},{"issue":"1","key":"1804_CR38","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/all.13239","volume":"73","author":"M Furue","year":"2018","unstructured":"Furue M, Yamamura K, Kido-Nakahara M, Nakahara T, Fukui Y. Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis. Allergy. 2018;73(1):29\u201336.","journal-title":"Allergy"},{"issue":"5","key":"1804_CR39","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.immuni.2020.04.008","volume":"52","author":"F Wang","year":"2020","unstructured":"Wang F, Kim BS. Itch: a paradigm of neuroimmune crosstalk. Immunity. 2020;52(5):753\u201366.","journal-title":"Immunity"},{"issue":"3","key":"1804_CR40","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3390\/vaccines9030303","volume":"9","author":"S Garcovich","year":"2021","unstructured":"Garcovich S, Maurelli M, Gisondi P, Peris K, Yosipovitch G, Girolomoni G. Pruritus as a distinctive feature of type 2 inflammation. Vaccines. 2021;9(3):303.","journal-title":"Vaccines"},{"issue":"4","key":"1804_CR41","doi-asserted-by":"publisher","first-page":"306","DOI":"10.23736\/S2784-8671.22.07265-6","volume":"157","author":"G Girolomoni","year":"2022","unstructured":"Girolomoni G, Maurelli M, Gisondi P. The emerging role of the neuroimmune cytokine interleukin-31 in chronic inflammatory skin diseases. Ital J Dermatol Venereol. 2022;157(4):306\u201312.","journal-title":"Ital J Dermatol Venereol"},{"issue":"9","key":"1804_CR42","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.3390\/jcm10091906","volume":"10","author":"M Furue","year":"2021","unstructured":"Furue M, Furue M. Interleukin-31 and pruritic skin. J Clin Med. 2021;10(9):1906.","journal-title":"J Clin Med"},{"issue":"3","key":"1804_CR43","doi-asserted-by":"publisher","first-page":"404","DOI":"10.2340\/00015555-2232","volume":"96","author":"S Bobko","year":"2016","unstructured":"Bobko S, Zeidler C, Osada N, Riepe C, Pfleiderer B, Pogatzki-Zahn E, et al. Intraepidermal nerve fibre density is decreased in lesional and inter-lesional prurigo nodularis and reconstitutes on healing of lesions. Acta Derm Venereol. 2016;96(3):404\u20136.","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"1804_CR44","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jid.2022.08.042","volume":"143","author":"K Agelopoulos","year":"2023","unstructured":"Agelopoulos K, Renkhold L, Wiegmann H, Dugas M, Suer A, Zeidler C, et al. Transcriptomic, epigenomic, and neuroanatomic signatures differ in chronic prurigo, atopic dermatitis, and brachioradial pruritus. J Investig Dermatol. 2023;143(2):264\u201372 e3.","journal-title":"J Investig Dermatol"},{"issue":"4","key":"1804_CR45","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1172\/JCI124609","volume":"129","author":"H Kabata","year":"2019","unstructured":"Kabata H, Artis D. Neuro-immune crosstalk and allergic inflammation. J Clin Investig. 2019;129(4):1475\u201382.","journal-title":"J Clin Investig"},{"issue":"5","key":"1804_CR46","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/j.1600-0560.2009.01484.x","volume":"37","author":"N Weigelt","year":"2010","unstructured":"Weigelt N, Metze D, St\u00e4nder S. Prurigo nodularis: systematic analysis of 58 histological criteria in 136 patients. J Cutan Pathol. 2010;37(5):578\u201386.","journal-title":"J Cutan Pathol"},{"issue":"2","key":"1804_CR47","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00403-019-01972-3","volume":"312","author":"JK Nguyen","year":"2020","unstructured":"Nguyen JK, Austin E, Huang A, Mamalis A, Jagdeo J. The IL-4\/IL-13 axis in skin fibrosis and scarring: mechanistic concepts and therapeutic targets. Arch Dermatol Res. 2020;312(2):81\u201392.","journal-title":"Arch Dermatol Res"},{"issue":"3","key":"1804_CR48","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.4049\/jimmunol.168.3.1139","volume":"168","author":"SP Atamas","year":"2002","unstructured":"Atamas SP, Luzina IG, Dai H, Wilt SG, White B. Synergy between CD40 ligation and IL-4 on fibroblast proliferation involves IL-4 receptor signaling. J Immunol. 2002;168(3):1139\u201345.","journal-title":"J Immunol"},{"issue":"7","key":"1804_CR49","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1016\/j.jid.2023.12.021","volume":"144","author":"JR Patel","year":"2024","unstructured":"Patel JR, Joel MZ, Lee KK, Kambala A, Cornman H, Oladipo O, et al. Single-cell RNA sequencing reveals dysregulated POSTN+WNT5A+ fibroblast subclusters in prurigo nodularis. J Investig Dermatol. 2024;144(7):1568\u201378 e5.","journal-title":"J Investig Dermatol"},{"issue":"1","key":"1804_CR50","doi-asserted-by":"publisher","first-page":"adv00375","DOI":"10.2340\/00015555-3702","volume":"101","author":"T Hashimoto","year":"2021","unstructured":"Hashimoto T, Nattkemper LA, Kim HS, Kursewicz CD, Fowler E, Shah SM, et al. Dermal periostin: a new player in itch of prurigo nodularis. Acta Derm Venereol. 2021;101(1):adv00375.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"1804_CR51","doi-asserted-by":"publisher","first-page":"5947","DOI":"10.1038\/s41467-021-26099-w","volume":"12","author":"A Kuzumi","year":"2021","unstructured":"Kuzumi A, Yoshizaki A, Matsuda KM, Kotani H, Norimatsu Y, Fukayama M, et al. Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis. Nat Commun. 2021;12(1):5947.","journal-title":"Nat Commun"},{"issue":"6","key":"1804_CR52","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1093\/bjd\/ljae052","volume":"190","author":"V Liao","year":"2024","unstructured":"Liao V, Cornman HL, Ma E, Kwatra SG. Prurigo nodularis: new insights into pathogenesis and novel therapeutics. Br J Dermatol. 2024;190(6):798\u2013810.","journal-title":"Br J Dermatol"},{"issue":"9","key":"1804_CR53","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1016\/j.jid.2021.02.749","volume":"141","author":"M Belzberg","year":"2021","unstructured":"Belzberg M, Alphonse MP, Brown I, Williams KA, Khanna R, Ho B, et al. Prurigo nodularis is characterized by systemic and cutaneous T helper 22 immune polarization. J Investig Dermatol. 2021;141(9):2208\u201318 e14.","journal-title":"J Investig Dermatol"},{"issue":"6","key":"1804_CR54","doi-asserted-by":"publisher","first-page":"100233","DOI":"10.1016\/j.xjidi.2023.100233","volume":"3","author":"CL Morgan","year":"2023","unstructured":"Morgan CL, Thomas M, Heywood BR, St\u00e4nder S, Kwatra SG, Jabbar-L\u00f3pez ZK, et al. Incident comorbidity, resource use, and all-cause mortality associated with prurigo nodularis: a United Kingdom retrospective database analysis. JID Innov. 2023;3(6):100233.","journal-title":"JID Innov"},{"issue":"11","key":"1804_CR55","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1097\/CM9.0000000000003013","volume":"137","author":"M Yin","year":"2024","unstructured":"Yin M, Zhong W, Zhou K, Dou X. Comorbidities of prurigo nodularis in Chinese patients: a multicenter retrospective study. Chin Med J (Engl). 2024;137(11):1360\u20132.","journal-title":"Chin Med J (Engl)"},{"issue":"5","key":"1804_CR56","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.jaad.2023.06.045","volume":"89","author":"MZ Joel","year":"2023","unstructured":"Joel MZ, Hydol-Smith J, Kambala A, Cornman HL, Kwatra SG. Prevalence and comorbidity burden of prurigo nodularis in United States adults enrolled in the All of Us research program. J Am Acad Dermatol. 2023;89(5):1056\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1804_CR57","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.jaci.2023.04.019","volume":"152","author":"N Alkon","year":"2023","unstructured":"Alkon N, Assen FP, Arnoldner T, Bauer WM, Medjimorec MA, Shaw LE, et al. Single-cell RNA sequencing defines disease-specific differences between chronic nodular prurigo and atopic dermatitis. J Allergy Clin Immunol. 2023;152(2):420\u201335.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1804_CR58","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.nefroe.2023.03.015","volume":"43","author":"P Molina","year":"2023","unstructured":"Molina P, Ojeda R, Blanco A, Alcalde G, Prieto-Velasco M, Arest\u00e9 N, et al. Etiopathogenesis of chronic kidney disease-associated pruritus: putting the pieces of the puzzle together. Nefrolog\u00eda (English Edition). 2023;43(1):48\u201362.","journal-title":"Nefrolog\u00eda (English Edition)"},{"issue":"2","key":"1804_CR59","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2340\/00015555-2492","volume":"97","author":"RI Kestner","year":"2017","unstructured":"Kestner RI, St\u00e4nder S, Osada N, Ziegler D, Metze D. Acquired reactive perforating dermatosis is a variant of prurigo nodularis. Acta Derm Venereol. 2017;97(2):249\u201354.","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"1804_CR60","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jdermsci.2022.02.004","volume":"105","author":"N Sutaria","year":"2022","unstructured":"Sutaria N, Marani M, Choi J, Roh YS, Parthasarathy V, Deng J, et al. Racial differences in dysregulation of the renin-angiotensin-aldosterone system in patients with prurigo nodularis. J Dermatol Sci. 2022;105(2):130\u20136.","journal-title":"J Dermatol Sci"},{"issue":"2","key":"1804_CR61","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3390\/genes15020146","volume":"15","author":"M Marani","year":"2024","unstructured":"Marani M, Madan V, Le TK, Deng J, Lee KK, Ma EZ, et al. Dysregulation of the skin-liver axis in prurigo nodularis: an integrated genomic, transcriptomic, and population-based analysis. Genes. 2024;15(2):146.","journal-title":"Genes"},{"issue":"7","key":"1804_CR62","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1111\/ijd.17652","volume":"64","author":"N Chalupczak","year":"2025","unstructured":"Chalupczak N, Devine M, Chang CH, Polaskey MT, Chovatiya R. Prevalence of metabolic diseases in patients with prurigo nodularis: a systematic review and meta-analysis. Int J Dermatol. 2025;64(7):1321\u20135.","journal-title":"Int J Dermatol"},{"issue":"6","key":"1804_CR63","first-page":"53","volume":"15","author":"J Han","year":"2022","unstructured":"Han J, Palomino A, Estupinan B, Wozniak A, Swan J. Psychiatric comorbidity in prurigo nodularis and the impact of socioeconomic status. J Clin Aesthet Dermatol. 2022;15(6):53\u20138.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"1","key":"1804_CR64","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00403-024-03566-0","volume":"317","author":"EZ Ma","year":"2024","unstructured":"Ma EZ, Parthasarathy V, Lee KK, Shahsavari S, Gage D, Akiska Y, et al. Elevated C-reactive protein levels and cardiovascular risk in prurigo nodularis patients with sleep disturbance: a multi-center cohort study. Arch Dermatol Res. 2024;317(1):87.","journal-title":"Arch Dermatol Res"},{"issue":"5","key":"1804_CR65","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1111\/bjd.20957","volume":"186","author":"S Wongvibulsin","year":"2022","unstructured":"Wongvibulsin S, Parthasarathy V, Pahalyants V, Murphy W, Sutaria N, Roh YS, et al. Latent class analysis identification of prurigo nodularis comorbidity phenotypes. Br J Dermatol. 2022;186(5):903\u20135.","journal-title":"Br J Dermatol"},{"issue":"11","key":"1804_CR66","doi-asserted-by":"publisher","first-page":"e984","DOI":"10.1111\/jdv.20038","volume":"38","author":"MP Pereira","year":"2024","unstructured":"Pereira MP, Gutsche A, Weisshaar E, Halvorsen JA, Wallengren J, Legat FJ, et al. Chronic nodular prurigo: association between comorbidities, itch and quality of life. J Eur Acad Dermatol Venereol. 2024;38(11):e984\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1804_CR67","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1001\/jamadermatol.2021.5307","volume":"158","author":"SG Kwatra","year":"2022","unstructured":"Kwatra SG. Prurigo nodularis. JAMA Dermatol. 2022;158(3):336.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1804_CR68","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.alit.2016.08.009","volume":"66","author":"MP Pereira","year":"2017","unstructured":"Pereira MP, St\u00e4nder S. Assessment of severity and burden of pruritus. Allergol Int. 2017;66(1):3\u20137.","journal-title":"Allergol Int"},{"issue":"3","key":"1804_CR69","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jaad.2018.04.044","volume":"79","author":"S Steinke","year":"2018","unstructured":"Steinke S, Zeidler C, Riepe C, Bruland P, Soto-Rey I, Storck M, et al. Humanistic burden of chronic pruritus in patients with inflammatory dermatoses: results of the European Academy of Dermatology and Venereology Network on Assessment of Severity and Burden of Pruritus (PruNet) cross-sectional trial. J Am Acad Dermatol. 2018;79(3):457\u201363 e5.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1804_CR70","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.jaad.2021.05.036","volume":"86","author":"KA Whang","year":"2022","unstructured":"Whang KA, Le TK, Khanna R, Williams KA, Roh YS, Sutaria N, et al. Health-related quality of life and economic burden of prurigo nodularis. J Am Acad Dermatol. 2022;86(3):573\u201380.","journal-title":"J Am Acad Dermatol"},{"key":"1804_CR71","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jdin.2023.07.009","volume":"13","author":"MZ Joel","year":"2023","unstructured":"Joel MZ, Taylor MT, Cornman HL, Kambala A, Reddy SV, Gabriel S, et al. Risk of incident sleep disorders in patients with prurigo nodularis: a population-level analysis using The Health Improvement Network. JAAD Int. 2023;13:39\u201345.","journal-title":"JAAD Int"},{"issue":"3","key":"1804_CR72","doi-asserted-by":"publisher","first-page":"adv00424","DOI":"10.2340\/00015555-3778","volume":"101","author":"EC Gwillim","year":"2021","unstructured":"Gwillim EC, Nattkemper L, Yosipovitch G. Impact of itch on sleep disturbance in patients with prurigo nodularis. Acta Derm Venereol. 2021;101(3):adv00424.","journal-title":"Acta Derm Venereol"},{"issue":"7","key":"1804_CR73","doi-asserted-by":"publisher","first-page":"e908","DOI":"10.1111\/jdv.19013","volume":"37","author":"L Misery","year":"2023","unstructured":"Misery L, Patras de Campaigno C, Taieb C, Th\u00e9ni\u00e9 C, Meyer C, Marqui\u00e9 A, et al. Impact of chronic prurigo nodularis on daily life and stigmatization. J Eur Acad Dermatol Venereol. 2023;37(7):e908\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"1804_CR74","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.1007\/s12325-025-03217-4","volume":"42","author":"SG Kwatra","year":"2025","unstructured":"Kwatra SG, Yang M, Martins B, Zion A, Liu J, Zahn J, et al. Prurigo nodularis patient-reported burden of sickness (PN TREK): a cross-sectional survey of patient-reported burden of disease in patients with PN from the US. Adv Ther. 2025;42(7):3455\u201371.","journal-title":"Adv Ther"},{"issue":"2","key":"1804_CR75","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1111\/jdv.13827","volume":"31","author":"KM Jorgensen","year":"2017","unstructured":"Jorgensen KM, Egeberg A, Gislason GH, Skov L, Thyssen JP. Anxiety, depression and suicide in patients with prurigo nodularis. J Eur Acad Dermatol Venereol. 2017;31(2):e106\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1804_CR76","doi-asserted-by":"publisher","first-page":"adv40677","DOI":"10.2340\/actadv.v104.40677","volume":"104","author":"W Jiang","year":"2024","unstructured":"Jiang W, Chen J, Li N, Wang X, Li C. Depression, anxiety and suicidal ideation in prurigo nodularis: a systematic review and meta-analysis. Acta Derm Venereol. 2024;104:adv40677.","journal-title":"Acta Derm Venereol"},{"issue":"10","key":"1804_CR77","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1016\/j.jid.2021.02.756","volume":"141","author":"S Wongvibulsin","year":"2021","unstructured":"Wongvibulsin S, Sutaria N, Williams KA, Huang AH, Choi J, Roh YS, et al. A nationwide study of prurigo nodularis: disease burden and healthcare utilization in the United States. J Investig Dermatol. 2021;141(10):2530\u20133 e1.","journal-title":"J Investig Dermatol"},{"issue":"1","key":"1804_CR78","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1001\/jamadermatol.2018.3912","volume":"155","author":"KM Beck","year":"2019","unstructured":"Beck KM, Yang EJ, Sekhon S, Bhutani T, Liao W. Dupilumab treatment for generalized prurigo nodularis. JAMA Dermatol. 2019;155(1):118\u201320.","journal-title":"JAMA Dermatol"},{"issue":"8","key":"1804_CR79","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1007\/s00105-014-2753-z","volume":"65","author":"F Schedel","year":"2014","unstructured":"Schedel F, Schurmann C, Metze D, St\u00e4nder S. Prurigo. Clinical definition and classification. Hautarzt. 2014;65(8):684\u201390.","journal-title":"Hautarzt"},{"issue":"4","key":"1804_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/itx.0000000000000042","volume":"5","author":"S St\u00e4nder","year":"2020","unstructured":"St\u00e4nder S, Pereira MP, Berger T, Zeidler C, Augustin M, Bobko S, et al. IFSI-Guideline on chronic prurigo including prurigo nodularis. ITCH. 2020;5(4):1\u201313.","journal-title":"ITCH"},{"issue":"10","key":"1804_CR81","first-page":"1039","volume":"17","author":"M Peckruhn","year":"2019","unstructured":"Peckruhn M, Elsner P, Tittelbach J. Eosinophilic dermatoses. JDDG. 2019;17(10):1039\u201351.","journal-title":"JDDG"},{"issue":"2","key":"1804_CR82","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s40475-021-00231-8","volume":"8","author":"Z Shepard","year":"2021","unstructured":"Shepard Z, Rios M, Solis J, Wand T, Henao-Mart\u00ednez AF, Franco-Paredes C, et al. Common dermatologic conditions in returning travelers. Curr Trop Med Rep. 2021;8(2):104\u201311.","journal-title":"Curr Trop Med Rep"},{"key":"1804_CR83","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40413-016-0110-7","volume":"9","author":"L Caraballo","year":"2016","unstructured":"Caraballo L, Zakzuk J, Lee BW, Acevedo N, Soh JY, S\u00e1nchez-Borges M, et al. Particularities of allergy in the Tropics. World Allergy Organ J. 2016;9:20.","journal-title":"World Allergy Organ J"},{"issue":"9","key":"1804_CR84","first-page":"e414","volume":"48","author":"T Satoh","year":"2021","unstructured":"Satoh T, Yokozeki H, Murota H, Tokura Y, Kabashima K, Takamori K, et al. 2020 guidelines for the diagnosis and treatment of prurigo. J Dermatol. 2021;48(9):e414\u201331.","journal-title":"J Dermatol"},{"issue":"1","key":"1804_CR85","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jaad.2020.03.049","volume":"83","author":"A Chiricozzi","year":"2020","unstructured":"Chiricozzi A, Maurelli M, Gori N, Argenziano G, De Simone C, Calabrese G, et al. Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo. J Am Acad Dermatol. 2020;83(1):39\u201345.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"1804_CR86","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1111\/jdv.15040","volume":"32","author":"J Polking","year":"2018","unstructured":"Polking J, Zeidler C, Schedel F, Osada N, August\u00edn M, Metze D, et al. Prurigo Activity Score (PAS): validity and reliability of a new instrument to monitor chronic prurigo. J Eur Acad Dermatol Venereol. 2018;32(10):1754\u201360.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1804_CR87","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40257-023-00818-z","volume":"25","author":"S Muller","year":"2024","unstructured":"Muller S, Zeidler C, St\u00e4nder S. Chronic prurigo including prurigo nodularis: new insights and treatments. Am J Clin Dermatol. 2024;25(1):15\u201333.","journal-title":"Am J Clin Dermatol"},{"key":"1804_CR88","unstructured":"Dermatology Life Quality Index (DLQI) [cited 2026 February 24]. Available from: https:\/\/www.cardiff.ac.uk\/medicine\/resources\/quality-of-life-questionnaires\/dermatology-life-quality-index."},{"key":"1804_CR89","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1477-7525-1-29","volume":"1","author":"RP Snaith","year":"2003","unstructured":"Snaith RP. The hospital anxiety and depression scale. Health Qual Life Outcomes. 2003;1:29.","journal-title":"Health Qual Life Outcomes"},{"key":"1804_CR90","unstructured":"Hospital Anxiety and Depression Scale (HADS) Questionnaire [cited 2026 February 24]. Available from: https:\/\/www.svri.org\/sites\/default\/files\/attachments\/2016-01-13\/HADS.pdf."},{"issue":"3 Suppl","key":"1804_CR91","first-page":"AB103","volume":"89","author":"D Bahloul","year":"2023","unstructured":"Bahloul D, Thomas RB, Rhoten S, H\u00e4usler N, St\u00e4nder S, Kim BS, et al. 43531 Validation of the Dermatology Life Quality Index (DLQI) in prurigo nodularis (PN) based on clinical studies of dupilumab in adults with PN. J Am Acad Dermatol. 2023;89(3 Suppl):AB103.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1804_CR92","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1001\/jamadermatol.2023.5519","volume":"160","author":"M Metz","year":"2024","unstructured":"Metz M, Zeidler C, Hawro T, Pereira M, Maurer M, Bonnekoh H, et al. Development and validation of a patient-reported outcome measure to assess disease control in chronic prurigo. JAMA Dermatol. 2024;160(2):187\u201393.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1804_CR93","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jaad.2008.04.006","volume":"59","author":"NS Desai","year":"2008","unstructured":"Desai NS, Poindexter GB, Monthrope YM, Bendeck SE, Swerlick RA, Chen SC. A pilot quality-of-life instrument for pruritus. J Am Acad Dermatol. 2008;59(2):234\u201344.","journal-title":"J Am Acad Dermatol"},{"key":"1804_CR94","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.70171","author":"LS Stahl","year":"2025","unstructured":"Stahl LS, Zeidler C, Loewenthal J, Royeck S, Augustin M, Bissonnette R, et al. The SWITCH algorithm: an expert consensus on treat-to-target criteria for chronic prurigo. J Eur Acad Dermatol Venereol. 2025. https:\/\/doi.org\/10.1111\/jdv.70171","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1804_CR95","doi-asserted-by":"publisher","first-page":"266","DOI":"10.2340\/00015555-1949","volume":"95","author":"S St\u00e4nder","year":"2015","unstructured":"St\u00e4nder S, Pogatzki-Zahn E, Stumpf A, Fritz F, Pfleiderer B, Ritzkat A, et al. Facing the challenges of chronic pruritus: a report from a multi-disciplinary medical itch centre in Germany. Acta Derm Venereol. 2015;95(3):266\u201371.","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"1804_CR96","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41591-023-02320-9","volume":"29","author":"G Yosipovitch","year":"2023","unstructured":"Yosipovitch G, Mollanazar N, St\u00e4nder S, Kwatra SG, Kim BS, Laws E, et al. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials. Nat Med. 2023;29(5):1180\u201390.","journal-title":"Nat Med"},{"issue":"2","key":"1804_CR97","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/jamadermatol.2024.4796","volume":"161","author":"S St\u00e4nder","year":"2025","unstructured":"St\u00e4nder S, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, et al. Efficacy and safety of nemolizumab in patients with moderate to severe prurigo nodularis: the OLYMPIA 1 randomized clinical phase 3 trial. JAMA Dermatol. 2025;161(2):147\u201356.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"1804_CR98","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.jaad.2016.02.1237","volume":"75","author":"KM Matsuda","year":"2016","unstructured":"Matsuda KM, Sharma D, Schonfeld AR, Kwatra SG. Gabapentin and pregabalin for the treatment of chronic pruritus. J Am Acad Dermatol. 2016;75(3):619\u201325 e6.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1804_CR99","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.jaad.2018.09.020","volume":"80","author":"AA Qureshi","year":"2019","unstructured":"Qureshi AA, Abate LE, Yosipovitch G, Friedman AJ. A systematic review of evidence-based treatments for prurigo nodularis. J Am Acad Dermatol. 2019;80(3):756\u201364.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1804_CR100","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.jaad.2017.08.025","volume":"77","author":"TA Kouwenhoven","year":"2017","unstructured":"Kouwenhoven TA, van de Kerkhof PCM, Kamsteeg M. Use of oral antidepressants in patients with chronic pruritus: a systematic review. J Am Acad Dermatol. 2017;77(6):1068\u201373 e7.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1804_CR101","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1177\/12034754231211797","volume":"27","author":"LE McCampbell","year":"2023","unstructured":"McCampbell LE, Zaino ML, Ranpariya M, Patel T, Feldman SR. Systemic medication for the treatment of prurigo nodularis\u2014A systematic review. J Cutan Med Surg. 2023;27(6):641\u20135.","journal-title":"J Cutan Med Surg"},{"issue":"17","key":"1804_CR102","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1056\/NEJMoa2301333","volume":"389","author":"SG Kwatra","year":"2023","unstructured":"Kwatra SG, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, et al. Phase 3 trial of nemolizumab in patients with prurigo nodularis. N Engl J Med. 2023;389(17):1579\u201389.","journal-title":"N Engl J Med"},{"issue":"7","key":"1804_CR103","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1001\/jamadermatol.2024.1464","volume":"160","author":"SG Kwatra","year":"2024","unstructured":"Kwatra SG, Bordeaux ZA, Parthasarathy V, Kollhoff AL, Alajmi A, Pritchard T, et al. Efficacy and safety of abrocitinib in prurigo nodularis and chronic pruritus of unknown origin: a nonrandomized controlled trial. JAMA Dermatol. 2024;160(7):717\u201324.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"1804_CR104","doi-asserted-by":"publisher","first-page":"546","DOI":"10.4168\/aair.2024.16.5.546","volume":"16","author":"J Lee","year":"2024","unstructured":"Lee J, Kim Y, Shin K, Kim HS, Ko HC, Kim MB, et al. Treatment with upadacitinib in refractory prurigo nodularis: a prospective cohort study. Allergy Asthma Immunol Res. 2024;16(5):546\u201354.","journal-title":"Allergy Asthma Immunol Res"},{"key":"1804_CR105","unstructured":"Kwatra S. Efficacy and safety of oral povorcitinib in patients with prurigo nodularis: 40-week results from a randomized, double-blind, placebo-controlled phase 2 study (Presentation D2T01.3F). 33rd European Academy of Dermatology and Venereology Congress; 2024 September 25\u201328; Amsterdam, The Netherlands."},{"key":"1804_CR106","unstructured":"European Medicines Agency. EMA confirms measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders [cited 2026 February 24]. Available from: https:\/\/www.ema.europa.eu\/en\/news\/ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic-inflammatory-disorders."},{"key":"1804_CR107","doi-asserted-by":"publisher","first-page":"101826","DOI":"10.1016\/j.eclinm.2023.101826","volume":"57","author":"H Sofen","year":"2023","unstructured":"Sofen H, Bissonnette R, Yosipovitch G, Silverberg JI, Tyring S, Loo WJ, et al. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor beta antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study. EClinicalMedicine. 2023;57:101826.","journal-title":"EClinicalMedicine"},{"issue":"4","key":"1804_CR108","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.jaci.2023.11.924","volume":"153","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Strober B, Feinstein B, Xu J, Guttman-Yassky E, Simpson EL, et al. Efficacy and safety of rademikibart (CBP-201), a next-generation mAb targeting IL-4Ra, in adults with moderate to severe atopic dermatitis: a phase 2 randomized trial (CBP-201-WW001). J Allergy Clin Immunol. 2024;153(4):1040\u20139 e12.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1804_CR109","doi-asserted-by":"publisher","first-page":"12411","DOI":"10.1038\/s41598-023-39311-2","volume":"13","author":"L Zhang","year":"2023","unstructured":"Zhang L, Ding Y, Wang Q, Pan W, Wei Z, Smith PA, et al. Preclinical immunological characterization of rademikibart (CBP-201), a next-generation human monoclonal antibody targeting IL-4Ra, for the treatment of Th2 inflammatory diseases. Sci Rep. 2023;13(1):12411.","journal-title":"Sci Rep"},{"issue":"3","key":"1804_CR110","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1007\/s12325-023-02755-z","volume":"41","author":"E Guttman-Yassky","year":"2024","unstructured":"Guttman-Yassky E, Simpson EL, Reich K, Kabashima K, Igawa K, Suzuki T, et al. Summary of research: an anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study. Adv Ther. 2024;41(3):928\u201331.","journal-title":"Adv Ther"},{"key":"1804_CR111","unstructured":"ClinicalTrials.gov. A phase 2 randomized, double-blind, placebo-controlled study to assess the efficacy and safety of barzolvolimab (CDX-0159) in patients with prurigo nodularis [cited 2026 February 24]. Available from: https:\/\/clinicaltrials.ucsf.edu\/trial\/NCT06366750."},{"issue":"11","key":"1804_CR112","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","volume":"35","author":"L Blonde","year":"2018","unstructured":"Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018;35(11):1763\u201374.","journal-title":"Adv Ther"},{"issue":"1","key":"1804_CR113","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/ced.14015","volume":"45","author":"K Sardana","year":"2020","unstructured":"Sardana K, Gupta A, Sinha S. An observational analysis of low-dose thalidomide in recalcitrant prurigo nodularis. Clin Exp Dermatol. 2020;45(1):92\u20136.","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"1804_CR114","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/jdv.14646","volume":"32","author":"T Klejtman","year":"2018","unstructured":"Klejtman T, Beylot-Barry M, Joly P, Richard MA, Debarbieux S, Misery L, et al. Treatment of prurigo with methotrexate: a multicentre retrospective study of 39 cases. J Eur Acad Dermatol Venereol. 2018;32(3):437\u201340.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"1804_CR115","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/1346-8138.16803","volume":"50","author":"HY Fang","year":"2023","unstructured":"Fang HY, Lian CH. The effectiveness and safety of dupilumab in the management of refractory prurigo nodularis in 45 Chinese patients: a real-life observational study. J Dermatol. 2023;50(8):1084\u20137.","journal-title":"J Dermatol"},{"issue":"5","key":"1804_CR116","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1111\/all.16478","volume":"80","author":"Z Zhao","year":"2025","unstructured":"Zhao Z, Song X, Shang Y, Liu L, Zheng R, Xia J, et al. Effectiveness and safety of dupilumab for prurigo nodularis in China: a multicentric and observational study. Allergy. 2025;80(5):1428\u201335.","journal-title":"Allergy"},{"issue":"1","key":"1804_CR117","first-page":"1","volume":"121","author":"A Aramburu-Gonz\u00e1lez","year":"2024","unstructured":"Aramburu-Gonz\u00e1lez A, Juli\u00e0-Manresa M, Izu-Belloso R, Rat\u00f3n-Nieto JR. Tratamiento del prurigo nodular con dupilumab: nuestra experiencia. Gac Med Bilbao. 2024;121(1):1\u20139.","journal-title":"Gac Med Bilbao"},{"issue":"4","key":"1804_CR118","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1159\/000529965","volume":"239","author":"Z Gao","year":"2023","unstructured":"Gao Z, Dou Y, Zhao P, Wang CJ, Zhang J. Successful treatment of prurigo nodularis by dupilumab: report of 24 patients. Dermatology. 2023;239(4):658\u201363.","journal-title":"Dermatology"},{"issue":"1","key":"1804_CR119","doi-asserted-by":"publisher","first-page":"3835433","DOI":"10.1155\/2023\/3835433","volume":"2023","author":"W Jing","year":"2023","unstructured":"Jing W, Yang D, Liu X, Li L, Lu T, Li X. Dupilumab therapy of prurigo nodularis: a single-center, real-life observational study. Dermatol Ther. 2023;2023(1):3835433.","journal-title":"Dermatol Ther"},{"key":"1804_CR120","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13030878","author":"C Paganini","year":"2024","unstructured":"Paganini C, Talamonti M, Maffei V, Di Raimondo C, Bianchi L, Galluzzo M. Dupilumab for treatment of prurigo nodularis: real-life effectiveness for up to 84 weeks. J Clin Med. 2024. https:\/\/doi.org\/10.3390\/jcm13030878.","journal-title":"J Clin Med"},{"issue":"10","key":"1804_CR121","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s40261-023-01307-1","volume":"43","author":"L Wei","year":"2023","unstructured":"Wei L, Yin M, Yang X, Chen J, Wu R, Yang H, et al. Effectiveness of dupilumab for chronic prurigo in Chinese patients: a real-world case series study. Clin Drug Investig. 2023;43(10):799\u2013805.","journal-title":"Clin Drug Investig"},{"issue":"4","key":"1804_CR122","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.abd.2022.09.008","volume":"98","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Li S, Wang Y, Zhao J. A real-world observational study of dupilumab treatment in adult patients with prurigo nodularis. An Bras Dermatol. 2023;98(4):440\u20138.","journal-title":"An Bras Dermatol"},{"issue":"1","key":"1804_CR123","doi-asserted-by":"publisher","first-page":"2624225","DOI":"10.1080\/09546634.2026.2624225","volume":"37","author":"Y Mima","year":"2026","unstructured":"Mima Y, Yamamoto M, Iozumi K. 24-week real world outcomes of nemolizumab in patients with prurigo nodularis. J Dermatol Treat. 2026;37(1):2624225.","journal-title":"J Dermatol Treat"},{"key":"1804_CR124","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17877","author":"W Sasaki","year":"2025","unstructured":"Sasaki W, Saito R, Suzuki K, Watanabe D, Minami-Hori M, Kamada H, et al. Clinical characteristics and risk factors for cutaneous manifestations associated with nemolizumab in atopic dermatitis: a multicenter retrospective study in Japan. J Dermatol. 2025. https:\/\/doi.org\/10.1111\/1346-8138.17877.","journal-title":"J Dermatol"},{"issue":"6","key":"1804_CR125","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.ad.2021.11.002","volume":"113","author":"A Docampo-Sim\u00f3n","year":"2022","unstructured":"Docampo-Sim\u00f3n A, S\u00e1nchez-Pujol MJ, Silvestre-Salvador JF. Update on chronic prurigo. Actas Dermosifiliogr. 2022;113(6):563\u201374.","journal-title":"Actas Dermosifiliogr"},{"issue":"9","key":"1804_CR126","doi-asserted-by":"publisher","first-page":"T866","DOI":"10.1016\/j.ad.2022.08.012","volume":"113","author":"J Espi\u00f1eira Sicre","year":"2022","unstructured":"Espi\u00f1eira Sicre J, Docampo Sim\u00f3n A, Silvestre Salvador JF. Chronic nodular prurigo: a retrospective study of 74 cases. Actas Dermosifiliogr. 2022;113(9):T866\u201373.","journal-title":"Actas Dermosifiliogr"},{"key":"1804_CR127","doi-asserted-by":"publisher","first-page":"adv44285","DOI":"10.2340\/actadv.v106.44285","volume":"106","author":"I Figueras-Nart","year":"2026","unstructured":"Figueras-Nart I, Serra-Baldrich E, St\u00e4nder S. Chronic prurigo: current knowledge, treatment strategies, future perspectives, and unmet needs. Acta Derm Venereol. 2026;106:adv44285.","journal-title":"Acta Derm Venereol"},{"key":"1804_CR128","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jdin.2024.03.025","volume":"16","author":"G Yosipovitch","year":"2024","unstructured":"Yosipovitch G, Kim BS, Kwatra SG, Mollanazar NK, St\u00e4nder S, Satoh T, et al. Dupilumab improves pruritus and skin lesions in patients with prurigo nodularis: pooled results from 2 phase 3 trials (LIBERTY-PN PRIME and PRIME2). JAAD Int. 2024;16:163\u201374.","journal-title":"JAAD Int"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01804-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01804-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01804-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T05:03:14Z","timestamp":1781758994000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01804-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":128,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1804"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01804-z","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"28 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ignasi Figueras has received honoraria or support for training activities, has acted as a speaker or consultant, or has participated in clinical trials from Abbvie, Almirall, Amgen, Apogee Therapeutics, Celldex Therapeutics, Celgene, Galderma, Incyte, Johnson & Johnson, Leo-Pharma, Lilly, Pfizer, Sanofi, Regeneron, Zuelling Pharma, and DKSH. \u00c1ngeles Fl\u00f3rez has received honoraria or support for training activities, has acted as a speaker or consultant, or has participated in clinical trials from Abbvie, Almirall, Amgen, Apogee Therapeutics, Celldex Therapeutics, Celgene, Galderma, Incyte, Janssen, Johnson & Johnson, Leo-Pharma, Lilly, Pfizer, Roche Farma, and Sanofi. Marc Juli\u00e0 Manresa has received honoraria or support for training activities, has acted as a speaker or consultant, or has participated in clinical trials from Abbvie, Almirall, Leo-Pharma, Lilly, Pfizer, and Sanofi. Francisco Javier Ortiz de Frutos has received honoraria for consultant or training activities from Novartis, Astellas, BDF, Uriach, Sanofi, GSK, Pfizer, Abbvie, Lilly, MSD, Leo and Almirall, or has participated in clinical trials from Astellas, Novartis, Bayer, Sanofi, Leo, Lilly, Pfizer, Abbvie; or has received grants for attendance of congress from Isdin, Menarini, Astellas, Novartis, MSD, Sanofi, Leti, and Leo. Jos\u00e9 Juan Pereyra has received honoraria for research from Novartis, AbbVie, and Sanofi; and for lecturing and other financial benefits from AbbVie, Almirall, Galderma, Janssen, Gebro-Pharma, Leo-Pharma, Novartis, Lilly, Novartis, Pfizer, Sanofi, and UCB. Bibiana P\u00e9rez has received honoraria or support for training activities, has acted as a speaker or consultant, or has participated in clinical trials from Abbvie, Almirall, Amgen, Galderma, Incyte, Leo-Pharma, Lilly, Pfizer, and Sanofi. Esther Serra-Baldrich has received honoraria or support for training activities, has acted as a speaker or consultant, or has participated in clinical trials from Abbvie, Almirall, Amgen, Apogee Therapeutics, Celldex Therapeutics, Galderma, Incyte, Leo-Pharma, Lilly, Pfizer, Roche Farma, and Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}